SICAGEN INDIA LIMITED Fair Value
SICAGEN · Services · Current price ₹55.53
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹112 | 4% ROE fading to 12% over ~3 yrs, on ₹125 book |
| Relative P/E | ₹201 | EPS × 43.9 peer-median P/E |
| Graham floor | ₹113 | Conservative floor: √(22.5 × EPS × book value/share) |
| Analyst target | — | No analyst coverage |
Is SICAGEN INDIA LIMITED undervalued?
DocStoX estimates the fair value of SICAGEN INDIA LIMITED at ₹137 per share, versus the current market price of ₹56. That puts the stock about +147.1% below our fair-value estimate, which we read as "Buy". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 3 independent methods: Residual income (₹112), Relative P/E (₹201), Graham floor (₹113). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹112 (bear) to ₹137 (base) to ₹201 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on SICAGEN INDIA LIMITED
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.